In this study, we developed novel thermal and redox-responsive
micelles based on the
Pluronic F127 tri-block copolymer and employed these for redox-responsive intratumor release of
bufalin, an anti-
cancer drug.
Pluronic F127 was first functionalized with carboxylate groups, and then assembled into
micelles. The HOOC-F127-COOH
micelles are 20 ± 4 nm in size at 37 °C, but expand to 281 ± 5 nm when cooled to 4 °C. This allows for the free diffusion of
bufalin into the micellar cores at low temperatures, while at 37 °C the
micelles are much more compact and the drug molecules can be effectively held in their interiors. A high encapsulation efficiency and loading content were obtained via drug incorporation at 4 °C. The drug-loaded
micelles were cross-linked with
cystamine, which contains a
disulfide bond responsive to the local cancer microenvironment. In vitro studies showed that drug release from the cross-linked
micelles was low under normal physiological conditions, but markedly accelerated upon exposure to conditions representative of the intracellular
tumor environment. Confocal microscopy revealed that the cross-linked
micelles gave high levels of drug release inside the cells. In vivo studies in mice showed the drug-loaded cross-linked
micelles have potent anti-
tumor activity, leading to high levels of apoptosis of
tumor cells and significant reductions in
tumor volume. The drug-loaded cross-linked
micelles did not significantly influence
body weight, and there was no evidence for detrimental off-target effects. These results indicate that the
Pluronic-based
micelles developed in this work are promising drug delivery systems for the targeted treatment of
cancer.